Asia On The Move: China FDA Appoints New Drug Review Head
This article was originally published in PharmAsia News
Executive Summary
Sun Xianze has become the China FDA’s fifth deputy commissioner, with a portfolio that includes oversight of drug reviews and approvals. The Chinese payer agency, the Ministry of Human Resources and Social Security, also has two new deputy ministers, while personnel changes have taken place at Takeda and BGI.